RxDoctor Payments Data

Carmen Gota, MD

Rheumatology · St. George, UTNPI 1568427052

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $40,950 of the $55,518 with a category attached, or 73.8%. GSK accounts for 91.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $31,719 and has fallen 83.6% since, to $5,217 in 2025. Among rheumatology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,518in general payments, 2019–2025

Across 263 payments — averaging $211.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$51K
  • Jazz Pharmaceuticals Inc.$1K
  • Amgen$923
  • Johnson & Johnson$589
  • AbbVie$547
  • UCB, Inc.$330
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$1,1672%
  • Speaking & faculty fees$40,95074%
  • Travel & lodging$8,50015%
  • Food & beverage$4,6498%
  • Education$2530%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,518 in reported general payments places this provider in the 90th percentile of 52 rheumatology providers in Utah.

See all rheumatology providers in Utah

Medicare billing

Part B allowed, 2024
$380,270
Medicare patients
444
Services billed
45,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib28$203,449
Humira(Cf) PenAdalimumab21$175,805
EnbrelEtanercept12$87,981
Teriparatide11$23,577
Hydroxychloroquine Sulfate197$9,482
MethotrexateMethotrexate Sodium307$7,684
Leflunomide85$6,333
Colchicine70$3,960
Prednisone246$2,707
Gabapentin125$2,275
Mycophenolate Mofetil20$2,048
Duloxetine Hcl48$1,340
Alendronate Sodium125$1,023
Methylprednisolone43$1,008
Bupropion XlBupropion Hcl14$856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$547$203,44928 claims
AmgenEnbrel$923$87,98112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 rheumatology providers in Utah.

Other rheumatology in St. George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →